Legal Opinion
Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc.
Court of Appeals for the Federal Circuit
Decided September 10, 2018No. 2017-2078; 2017-2134PublishedCited by 26 opinions
1Opinion of the Court
Opinion dissenting filed by Circuit Judge NEWMAN
Opinion for the court filed by Circuit Judge TARANTO.
*1313Before us are patents that claim the administration of a medication containing the active ingredient 4-aminopyridine (4-AP) to improve walking in individuals with multiple sclerosis. Acorda Therapeutics, Inc., holds New Drug Application No. 022250, approved by the U.S. Food and Drug Administration (FDA). Pursuant to that approval, Acorda markets, under the name "Ampyra®," 10 milligram 4-AP sustained-release tablets for twice-daily oral administration. In the FDA's Approved Drug Products with…
2Cases cited16 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.Supreme Court of the United States · 2002
- Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007
- Eurand, Inc. v. Mylan Pharmaceuticals Inc.Court of Appeals for the Federal Circuit · 2012
11 more not listed; retrieve them via the Exa API.
3Cited by26 opinions
- Return Mail, Inc. v. U.S. Postal Serv.Supreme Court of the United States · 2019
- Bradium Techs. LLC v. Andrei IANCUCourt of Appeals for the Federal Circuit · 2019
- Btg International Limited v. Amneal Pharmaceuticals LLCCourt of Appeals for the Federal Circuit · 2019
- University of Strathclyde v. Clear-Vu Lighting LLCCourt of Appeals for the Federal Circuit · 2021
- BTG Int'l Ltd. v. Amneal Pharm. LLCDistrict Court, D. New Jersey · 2018
21 more not listed; retrieve them via the Exa API.